Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Advances in oral immunomodulating therapies in relapsing multiple sclerosis.

Derfuss T, Mehling M, Papadopoulou A, Bar-Or A, Cohen JA, Kappos L.

Lancet Neurol. 2020 Feb 11. pii: S1474-4422(19)30391-6. doi: 10.1016/S1474-4422(19)30391-6. [Epub ahead of print] Review.

PMID:
32059809
2.

PARP-1 deregulation in multiple sclerosis.

Meira M, Sievers C, Hoffmann F, Bodmer H, Derfuss T, Kuhle J, Haghikia A, Kappos L, Lindberg RL.

Mult Scler J Exp Transl Clin. 2019 Dec 16;5(4):2055217319894604. doi: 10.1177/2055217319894604. eCollection 2019 Oct-Dec.

3.

New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis.

Sinnecker T, Ruberte E, Schädelin S, Canova V, Amann M, Naegelin Y, Penner IK, Müller J, Kuhle J, Décard B, Derfuss T, Kappos L, Granziera C, Wuerfel J, Magon S, Yaldizli Ö.

J Neurol. 2020 Jan;267(1):192-202. doi: 10.1007/s00415-019-09565-w. Epub 2019 Oct 14.

PMID:
31612322
4.

Hepatitis E virus infections in patients with MS on oral disease-modifying treatment.

Diebold M, Fischer-Barnicol B, Tsagkas C, Kuhle J, Kappos L, Derfuss T, Décard BF.

Neurol Neuroimmunol Neuroinflamm. 2019 Jul 11;6(5). pii: e594. doi: 10.1212/NXI.0000000000000594. Print 2019 Sep.

5.

PML with dimethyl fumarate-No convincing case against natalizumab.

Diebold M, Altersberger V, Décard BF, Kappos L, Derfuss T, Lorscheider J.

Mult Scler. 2019 Oct;25(12):1687-1688. doi: 10.1177/1352458519872894. Epub 2019 Aug 22. No abstract available.

PMID:
31436113
6.

GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis.

Galli E, Hartmann FJ, Schreiner B, Ingelfinger F, Arvaniti E, Diebold M, Mrdjen D, van der Meer F, Krieg C, Nimer FA, Sanderson N, Stadelmann C, Khademi M, Piehl F, Claassen M, Derfuss T, Olsson T, Becher B.

Nat Med. 2019 Aug;25(8):1290-1300. doi: 10.1038/s41591-019-0521-4. Epub 2019 Jul 22.

7.

A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence.

Diebold M, Altersberger V, Décard BF, Kappos L, Derfuss T, Lorscheider J.

Mult Scler. 2019 Oct;25(12):1682-1685. doi: 10.1177/1352458519852100. Epub 2019 Jun 18.

PMID:
31208265
8.

Antigen Extraction and B Cell Activation Enable Identification of Rare Membrane Antigen Specific Human B Cells.

Zimmermann M, Rose N, Lindner JM, Kim H, Gonçalves AR, Callegari I, Syedbasha M, Kaufmann L, Egli A, Lindberg RLP, Kappos L, Traggiai E, Sanderson NSR, Derfuss T.

Front Immunol. 2019 Apr 16;10:829. doi: 10.3389/fimmu.2019.00829. eCollection 2019.

9.

A case of concomitant psoriasis and multiple sclerosis: Secukinumab and rituximab exert dichotomous effects in two autoimmune conditions.

Diebold M, Müller S, Derfuss T, Décard BF.

Mult Scler Relat Disord. 2019 Jun;31:38-40. doi: 10.1016/j.msard.2019.03.009. Epub 2019 Mar 9.

PMID:
30901703
10.

Quantitative 7T MRI does not detect occult brain damage in neuromyelitis optica.

Pasquier B, Borisow N, Rasche L, Bellmann-Strobl J, Ruprecht K, Niendorf T, Derfuss TJ, Wuerfel J, Paul F, Sinnecker T.

Neurol Neuroimmunol Neuroinflamm. 2019 Mar 7;6(3):e541. doi: 10.1212/NXI.0000000000000541. eCollection 2019 May.

11.

The monoclonal antibody GNbAC1: targeting human endogenous retroviruses in multiple sclerosis.

Diebold M, Derfuss T.

Ther Adv Neurol Disord. 2019 Mar 7;12:1756286419833574. doi: 10.1177/1756286419833574. eCollection 2019. Review.

12.

Magnetic resonance imaging in immune-mediated myelopathies.

Wendebourg MJ, Nagy S, Derfuss T, Parmar K, Schlaeger R.

J Neurol. 2019 Jan 29. doi: 10.1007/s00415-019-09206-2. [Epub ahead of print] Review.

PMID:
30694379
13.

Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis.

Naegelin Y, Naegelin P, von Felten S, Lorscheider J, Sonder J, Uitdehaag BMJ, Scotti B, Zecca C, Gobbi C, Kappos L, Derfuss T.

JAMA Neurol. 2019 Mar 1;76(3):274-281. doi: 10.1001/jamaneurol.2018.4239.

14.

Central Slab versus Whole Brain to Measure Brain Atrophy in Multiple Sclerosis.

Ruberte E, Sinnecker T, Amann M, Gaetano L, Naegelin Y, Penner IK, Kuhle J, Derfuss T, Kappos L, Granziera C, Wuerfel J, Yaldizli Ö.

Eur Neurol. 2018;80(3-4):207-214. doi: 10.1159/000495798. Epub 2019 Jan 3.

PMID:
30605898
15.

Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study.

Jensen PEH, Warnke C, Ingenhoven K, Piccoli L, Gasis M, Hermanrud C, Fernandez-Rodriguez BM, Ryner M, Kramer D, Link J, Ramanujam R, Auer M, Buck D, Grummel V, Bertotti E, Fissolo N, Oliver-Martos B, Nytrova P, Khalil M, Guger M, Rathmaier S, Sievers-Stober C, Lindberg RLP, Hässler S, Bachelet D, Aktas O, Donnellan N, Lawton A, Hemmer B, Havrdova EK, Kieseier B, Hartung HP, Comabella M, Montalban X, Derfuss T, Sellebjerg F, Dönnes P, Pallardy M, Spindeldreher S, Broët P, Deisenhammer F, Fogdell-Hahn A, Sorensen PS; ABIRISK Consortium.

J Neuroimmunol. 2019 Jan 15;326:19-27. doi: 10.1016/j.jneuroim.2018.11.002. Epub 2018 Nov 7.

PMID:
30447419
16.

Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus.

Pröbstel AK, Thanei M, Erni B, Lecourt AC, Branco L, André R, Roux-Lombard P, Koenig KF, Huynh-Do U, Ribi C, Chizzolini C, Kappos L, Trendelenburg M, Derfuss T; Swiss Systemic Lupus Erythematosus Cohort Study Group.

Rheumatology (Oxford). 2019 May 1;58(5):908-913. doi: 10.1093/rheumatology/key282.

PMID:
30265368
17.

Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis.

Naegelin Y, Rasenack M, Andelova M, Von Felten S, Fischer-Barnicol B, Amann M, Mehling M, Kappos L, Sprenger T, Derfuss T.

Mult Scler Relat Disord. 2018 Oct;25:14-20. doi: 10.1016/j.msard.2018.07.005. Epub 2018 Jul 6.

18.

Anti-Myelin Oligodendrocyte Glycoprotein Antibody-Associated Central Nervous System Demyelination-A Novel Disease Entity?

Weber MS, Derfuss T, Brück W.

JAMA Neurol. 2018 Aug 1;75(8):909-910. doi: 10.1001/jamaneurol.2018.1055. No abstract available.

PMID:
29913011
19.

Testosterone and estrogen in multiple sclerosis: from pathophysiology to therapeutics.

Collongues N, Patte-Mensah C, De Seze J, Mensah-Nyagan AG, Derfuss T.

Expert Rev Neurother. 2018 Jun;18(6):515-522. doi: 10.1080/14737175.2018.1481390. Epub 2018 Jun 6. Review.

PMID:
29799288
20.

Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.

Lorscheider J, Benkert P, Lienert C, Hänni P, Derfuss T, Kuhle J, Kappos L, Yaldizli Ö.

Mult Scler. 2018 May;24(6):777-785. doi: 10.1177/1352458518768433. Epub 2018 Apr 24.

PMID:
29685071
21.

Extensive bilateral brain lesions in neuromyelitis optica spectrum disorders.

Décard BF, Derfuss T.

Mult Scler. 2018 Aug;24(9):1262-1263. doi: 10.1177/1352458518771888. Epub 2018 Apr 20. No abstract available.

PMID:
29676200
22.

Defining distinct features of anti-MOG antibody associated central nervous system demyelination.

Weber MS, Derfuss T, Metz I, Brück W.

Ther Adv Neurol Disord. 2018 Mar 29;11:1756286418762083. doi: 10.1177/1756286418762083. eCollection 2018. Review.

23.

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F.

Mult Scler. 2018 Feb;24(2):96-120. doi: 10.1177/1352458517751049. Epub 2018 Jan 20. Erratum in: Mult Scler. 2020 Feb 4;:1352458520906383.

PMID:
29353550
24.

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F.

Eur J Neurol. 2018 Feb;25(2):215-237. doi: 10.1111/ene.13536. Epub 2018 Jan 19. Erratum in: Eur J Neurol. 2018 Mar;25(3):605.

PMID:
29352526
25.

PML risk and natalizumab: the elephant in the room.

Derfuss T, Kappos L.

Lancet Neurol. 2017 Nov;16(11):864-865. doi: 10.1016/S1474-4422(17)30335-6. Epub 2017 Sep 29. No abstract available.

PMID:
28969985
26.

Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis.

Diebold M, Sievers C, Bantug G, Sanderson N, Kappos L, Kuhle J, Lindberg RLP, Derfuss T.

J Autoimmun. 2018 Jan;86:39-50. doi: 10.1016/j.jaut.2017.09.009. Epub 2017 Sep 27.

PMID:
28958667
27.

Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis.

Kappos L, Arnold DL, Bar-Or A, Camm AJ, Derfuss T, Sprenger T, Davies M, Piotrowska A, Ni P, Harada T.

Mult Scler. 2018 Oct;24(12):1605-1616. doi: 10.1177/1352458517728343. Epub 2017 Sep 15.

28.

α4-integrin receptor desaturation and disease activity return after natalizumab cessation.

Derfuss T, Kovarik JM, Kappos L, Savelieva M, Chhabra R, Thakur A, Zhang Y, Wiendl H, Tomic D.

Neurol Neuroimmunol Neuroinflamm. 2017 Aug 25;4(5):e388. doi: 10.1212/NXI.0000000000000388. eCollection 2017 Sep.

29.

Daclizumab for the treatment of multiple sclerosis.

Papadopoulou A, Derfuss T, Sprenger T.

Neurodegener Dis Manag. 2017 Oct;7(5):279-297. doi: 10.2217/nmt-2017-0023. Epub 2017 Aug 29. Review.

PMID:
28849702
30.

Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy.

Bischof A, Manigold T, Barro C, Heijnen I, Berger CT, Derfuss T, Kuhle J, Daikeler T.

Ann Rheum Dis. 2018 Jul;77(7):1093-1094. doi: 10.1136/annrheumdis-2017-212045. Epub 2017 Jul 25. No abstract available.

PMID:
28743789
31.

Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop.

Amato MP, Derfuss T, Hemmer B, Liblau R, Montalban X, Soelberg Sørensen P, Miller DH; 2016 ECTRIMS Focused Workshop Group.

Mult Scler. 2017 Jan 6:1352458516686847. doi: 10.1177/1352458516686847. [Epub ahead of print]

32.

Expression of the Antioxidative Enzyme Peroxiredoxin 2 in Multiple Sclerosis Lesions in Relation to Inflammation.

Voigt D, Scheidt U, Derfuss T, Brück W, Junker A.

Int J Mol Sci. 2017 Apr 4;18(4). pii: E760. doi: 10.3390/ijms18040760.

33.

Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.

Link J, Ramanujam R, Auer M, Ryner M, Hässler S, Bachelet D, Mbogning C, Warnke C, Buck D, Hyldgaard Jensen PE, Sievers C, Ingenhoven K, Fissolo N, Lindberg R, Grummel V, Donnellan N, Comabella M, Montalban X, Kieseier B, Soelberg Sørensen P, Hartung HP, Derfuss T, Lawton A, Sikkema D, Pallardy M, Hemmer B, Deisenhammer F, Broët P, Dönnes P, Davidson J, Fogdell-Hahn A; ABIRISK Consortium.

PLoS One. 2017 Feb 7;12(2):e0170395. doi: 10.1371/journal.pone.0170395. eCollection 2017.

34.

Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.

Havla J, Warnke C, Derfuss T, Kappos L, Hartung HP, Hohlfeld R.

Dtsch Arztebl Int. 2016 Dec 26;113(51-52):879-886. doi: 10.3238/arztebl.2016.0879. Review.

35.

Cocapture of cognate and bystander antigens can activate autoreactive B cells.

Sanderson NS, Zimmermann M, Eilinger L, Gubser C, Schaeren-Wiemers N, Lindberg RL, Dougan SK, Ploegh HL, Kappos L, Derfuss T.

Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):734-739. doi: 10.1073/pnas.1614472114. Epub 2017 Jan 5.

36.

Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial.

Kappos L, Arnold DL, Bar-Or A, Camm J, Derfuss T, Kieseier BC, Sprenger T, Greenough K, Ni P, Harada T.

Lancet Neurol. 2016 Oct;15(11):1148-59. doi: 10.1016/S1474-4422(16)30192-2. Epub 2016 Aug 16.

PMID:
27543447
37.

Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials.

Derfuss T, Ontaneda D, Nicholas J, Meng X, Hawker K.

Mult Scler Relat Disord. 2016 Jul;8:124-30. doi: 10.1016/j.msard.2016.05.015. Epub 2016 May 24.

38.

[Cell depletion and myoablation for neuroimmunological diseases].

Diebold M, Kappos L, Derfuss T.

Nervenarzt. 2016 Aug;87(8):814-20. doi: 10.1007/s00115-016-0156-3. Review. German.

PMID:
27389598
39.

Immunological treatment of multiple sclerosis.

Diebold M, Derfuss T.

Semin Hematol. 2016 Apr;53 Suppl 1:S54-7. doi: 10.1053/j.seminhematol.2016.04.016. Epub 2016 Apr 7. Review.

PMID:
27312167
40.

Promising Oral Compounds for the Treatment of Multiple Sclerosis: A Glance into the Future.

Décard BF, Derfuss T.

Semin Neurol. 2016 Apr;36(2):128-39. doi: 10.1055/s-0036-1580720. Epub 2016 Apr 26. Review.

PMID:
27116719
41.

Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development.

Meira M, Sievers C, Hoffmann F, Haghikia A, Rasenack M, Décard BF, Kuhle J, Derfuss T, Kappos L, Lindberg RL.

Neurol Neuroimmunol Neuroinflamm. 2016 Mar 31;3(3):e223. doi: 10.1212/NXI.0000000000000223. eCollection 2016 Jun.

42.

Multiple Sclerosis and Antibodies against KIR4.1.

Pröbstel AK, Kuhle J, Lecourt AC, Vock I, Sanderson NS, Kappos L, Derfuss T.

N Engl J Med. 2016 Apr 14;374(15):1496-8. doi: 10.1056/NEJMc1507131. No abstract available.

PMID:
27074084
43.

Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa.

Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius Å, Liman V, Norgren N, Blennow K, Zetterberg H.

Clin Chem Lab Med. 2016 Oct 1;54(10):1655-61. doi: 10.1515/cclm-2015-1195.

PMID:
27071153
44.

The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.

Disanto G, Benkert P, Lorscheider J, Mueller S, Vehoff J, Zecca C, Ramseier S, Achtnichts L, Findling O, Nedeltchev K, Radue EW, Sprenger T, Stippich C, Derfuss T, Louvion JF, Kamm CP, Mattle HP, Lotter C, Du Pasquier R, Schluep M, Pot C, Lalive PH, Yaldizli Ö, Gobbi C, Kappos L, Kuhle J; SMSC Scientific Board.

PLoS One. 2016 Mar 31;11(3):e0152347. doi: 10.1371/journal.pone.0152347. eCollection 2016.

45.

Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy.

Rust H, Kuhle J, Kappos L, Derfuss T.

Neurol Neuroimmunol Neuroinflamm. 2016 Mar 9;3(2):e215. doi: 10.1212/NXI.0000000000000215. eCollection 2016 Apr. No abstract available.

46.

Disease activity return after natalizumab cessation in multiple sclerosis.

Rasenack M, Derfuss T.

Expert Rev Neurother. 2016 May;16(5):587-94. doi: 10.1586/14737175.2016.1168295. Epub 2016 Apr 6. Review.

PMID:
26988737
47.

Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity.

Kuhle J, Barro C, Disanto G, Mathias A, Soneson C, Bonnier G, Yaldizli Ö, Regeniter A, Derfuss T, Canales M, Schluep M, Du Pasquier R, Krueger G, Granziera C.

Mult Scler. 2016 Oct;22(12):1550-1559. Epub 2016 Jan 11.

PMID:
26754800
48.

Efficacy and Safety of Fingolimod in an Unselected Patient Population.

Rasenack M, Rychen J, Andelova M, Naegelin Y, Stippich C, Kappos L, Lindberg RL, Sprenger T, Derfuss T.

PLoS One. 2016 Jan 6;11(1):e0146190. doi: 10.1371/journal.pone.0146190. eCollection 2016.

49.

Optimizing treatment success in multiple sclerosis.

Ziemssen T, Derfuss T, de Stefano N, Giovannoni G, Palavra F, Tomic D, Vollmer T, Schippling S.

J Neurol. 2016 Jun;263(6):1053-65. doi: 10.1007/s00415-015-7986-y. Epub 2015 Dec 24. Review.

50.

Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid.

Wuhrer M, Selman MH, McDonnell LA, Kümpfel T, Derfuss T, Khademi M, Olsson T, Hohlfeld R, Meinl E, Krumbholz M.

J Neuroinflammation. 2015 Dec 18;12:235. doi: 10.1186/s12974-015-0450-1.

Supplemental Content

Loading ...
Support Center